MedTrace Logo

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

NCT01603420 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2016-03-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effects on prostate cancer using radiation therapy with or without chemotherapy.

Conditions

Interventions

DRUG

Luteinizing hormone-releasing hormone (LHRH)

Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.

DRUG

Docetaxel

Docetaxel 20mg/m2 IV every 7 days x 8 weeks.

OTHER

Conformal Radiation Therapy (RT)

1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).

Sponsors & Collaborators

  • Proton Collaborative Group

    lead NETWORK

Principal Investigators

  • Carlos Vargas, MD · Proton Collaborative Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01603420 on ClinicalTrials.gov